Modified sugar molecules have been developed by researchers as antiviral materials which are non-toxic to humans, according to a new study.
List view / Grid view
Filter the results
Researchers have developed a new body-on-chip technology that can demonstrate the pharmacokinetics and pharmacodynamics of drugs in a pre-clinical setting without the need for animal testing.
A collaboration between Elsevier and the FDA will present an algorithm for the accurate prediction of drug-induced liver injury. Drug Target Review investigates the benefits this toxicology project will bring to the drug discovery industry.
Researchers have created two new cellular models that can be used in the study of ocular diseases and drug testing.
Researchers have made a ‘Liver-Chip’ which is able to demonstrate the toxic effects of drug candidates and compounds in human patients.
Researchers have used fullerene compounds to cause NSCLC cell death in cell and animal models, which exhibited low toxicity for healthy cells.
The worldwide market for in vitro toxicology and toxicity testing is predicted to be worth $12.7 billion by the end of the forecast period.
Researchers have used a high-throughput screening method to test over 125,000 molecules and identify a new class of antibiotics.
A study has predicted that the global in vitro toxicology market will rise by 8.2 percent in its forecast period.
A high-throughput approach for measuring intracellular ATP levels to access compound-mediated cellular toxicity
Many drugs fail in clinical trials due to toxicity-related issues; therefore, drug-mediated cellular toxicity should be determined at an early stage in the drug discovery value chain. There are many assay systems that can be utilised to measure cellular toxicity. In this article we demonstrate that intracellular ATP concentrations are…
Stem cell-based technologies lay the basis for pioneering approaches in drug screening, toxicology testing, and regenerative medicine. The constant supply of high cell numbers in consistent quality needs scalable culture systems and standardised process conditions.
This whitepaper explains how you can find ways to optimise the holistic preclinical development process...
In the annual report of the Chief Medical Officer, 1 Dame Sally Davies has declared that we are part of ‘generation genome’ – the era in which we reap the rewards of our advances in genomic technologies and improvements in our understanding of the whole genome in human health.